---
title: "Bell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293268981.md"
description: "Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals (TLPPF) with an A$19.00 price target. This follows a recent Buy from Citi, while RBC Capital downgraded the stock to Hold on July 16."
datetime: "2026-07-21T00:35:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293268981.md)
  - [en](https://longbridge.com/en/news/293268981.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293268981.md)
---

# Bell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$19.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Hester covers the Healthcare sector, focusing on stocks such as Imugene, Mesoblast Limited, and Aroa Biosurgery Ltd. According to TipRanks, Hester has an average return of 8.8% and a 48.30% success rate on recommended stocks.

In addition to Bell Potter, Telix Pharmaceuticals also received a Buy from Citi’s Laura Sutcliffe in a report issued on July 15. However, on July 16, RBC Capital downgraded Telix Pharmaceuticals (Other OTC: TLPPF) to a Hold.

### Related Stocks

- [TLX.AU](https://longbridge.com/en/quote/TLX.AU.md)
- [TLX.US](https://longbridge.com/en/quote/TLX.US.md)
- [IMU.AU](https://longbridge.com/en/quote/IMU.AU.md)
- [MSB.AU](https://longbridge.com/en/quote/MSB.AU.md)
- [MESO.US](https://longbridge.com/en/quote/MESO.US.md)
- [ARX.AU](https://longbridge.com/en/quote/ARX.AU.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [Citi Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)](https://longbridge.com/en/news/292688877.md)
- [Telix appoints three new non-executive directors to expanded board](https://longbridge.com/en/news/293260571.md)
- [Bell Potter Reaffirms Their Buy Rating on Vulcan Energy Resources Ltd. (VUL)](https://longbridge.com/en/news/294437331.md)
- [Canaccord Genuity Sticks to Its Buy Rating for Botanix Pharmaceuticals Limited (BOT)](https://longbridge.com/en/news/294282154.md)
- [Ord Minnett Sticks to Its Buy Rating for Meteoric Resources NL (MEI)](https://longbridge.com/en/news/294299722.md)